Your Health, We Care
Release date: 2024-08-15 17:52:00 Recommended: 118
As a targeted drug targeting RET mutations, Selpercatinib can block the signaling pathway of tumors, and has performed well in the treatment of advanced or metastatic cancers, making it suitable for patients with a variety of cancers.
Selpercatinib has been approved for marketing in China, and the indications of the drug are not limited to cholangiocarcinoma and lymphoid tumors.
Treatment of locally advanced or metastatic, FDA-approved testing-confirmed RET fusion-positive adult patients.
Treatment of patients 2 years of age and older with advanced or metastatic medullary thyroid cancer with RET mutations confirmed by an FDA-approved test.
Selpercatinib plays an important role in the treatment of a variety of diseases, and precautions during use should also be paid attention to.
Patients with uncontrolled hypertension should not start Selpercatinib. Blood pressure should be monitored regularly during treatment, and antihypertensive medications should be adjusted as appropriate. Depending on the severity of hypertension, the drug may be suspended, reduced, or discontinued.
Patients at risk for QT interval prolongation should be monitored, particularly those with a history of arrhythmias or severe heart failure. QT interval and electrolyte levels are assessed regularly before and during treatment, and the frequency of monitoring is adjusted according to risk factors.
It is important to be aware of possible drug interactions during the use of this medicine.
Selpercatinib is a moderate CYP2C8 inhibitor and a weak CYP3A inhibitor. Co-use with these substrates increases their plasma concentrations and may increase the risk of adverse effects. Co-use with these substrates should be avoided and, if unavoidable, follow the recommendations on the relevant drug label.
Selpercatinib is a P-gp inhibitor, and concomitant use with P-gp substrates increases plasma concentrations of these substrates, possibly increasing the risk of associated adverse effects. Combination with P-gp substrates should be avoided, and if it is unavoidable, refer to the instructions for use of the substrate drug.
[Warm tips] It is recommended to use a diary or mobile app to record the daily medication time and dosage to better manage your treatment process.
